Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Intangibles: 2012-2024

Historic Intangibles for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $541.8 million.

  • Ani Pharmaceuticals' Intangibles fell 12.29% to $499.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $499.8 million, marking a year-over-year decrease of 12.29%. This contributed to the annual value of $541.8 million for FY2024, which is 159.24% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Intangibles stood at $541.8 million for FY2024, which was up 159.24% from $209.0 million recorded in FY2023.
  • Ani Pharmaceuticals' Intangibles' 5-year high stood at $541.8 million during FY2024, with a 5-year trough of $188.5 million in FY2020.
  • In the last 3 years, Ani Pharmaceuticals' Intangibles had a median value of $251.6 million in 2022 and averaged $334.2 million.
  • Its Intangibles has fluctuated over the past 5 years, first skyrocketed by 165.50% in 2021, then slumped by 49.72% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Intangibles (Yearly) stood at $188.5 million in 2020, then skyrocketed by 165.50% to $500.5 million in 2021, then plummeted by 49.72% to $251.6 million in 2022, then decreased by 16.94% to $209.0 million in 2023, then spiked by 159.24% to $541.8 million in 2024.